Disrupt or be disrupted, experts warn pharmaPharma is playing catch-up with digital technology – but in this age of big data and AI, there Share XDisrupt or be disrupted, experts warn pharmahttps://pharmaphorum.com/views-analysis-sales-marketing/disrupt-disrupted-experts-warn-pharma/
How to make pharma marketing content unskippableAs long as pharma companies could afford an army of reps to get their advertising messaging directly to Share XHow to make pharma marketing content unskippablehttps://pharmaphorum.com/views-analysis-sales-marketing/how-to-make-pharma-marketing-content-unskippable/
Insight, market monitoring and assessing whether a brand plan is fit for purposeThis article is the last in a series of three from Osprey Health Consulting. In this third article Share XInsight, market monitoring and assessing whether a brand plan is fit for purposehttps://pharmaphorum.com/views-analysis-sales-marketing/insight-market-monitoring-and-assessing-whether-a-brand-plan-is-fit-for-purpose/
Is the pharma gender gap starting to close?When Emma Walmsley took the reins of GlaxoSmithKline (GSK) in 2016, becoming the first woman to head up Share XIs the pharma gender gap starting to close?https://pharmaphorum.com/views-analysis-sales-marketing/is-the-pharma-gender-gap-starting-to-close/
AstraZeneca may have hit rock bottom, but can it rise to new heights?Back in 2014, Pascal Soriot CEO of AstraZeneca managed to stave off a takeover bid from Pfizer with Share XAstraZeneca may have hit rock bottom, but can it rise to new heights?https://pharmaphorum.com/views-analysis-sales-marketing/astrazeneca-rise-new-heights/
Brand planning in complex and uncertain marketsIn our first article we addressed the modern challenges to strategic planning; the growing complexity and uncertainty that Share XBrand planning in complex and uncertain marketshttps://pharmaphorum.com/views-analysis-sales-marketing/brand-planning-in-complex-and-uncertain-markets/
Are dual ARVs the new frontier in a maturing HIV market?Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and Share XAre dual ARVs the new frontier in a maturing HIV market?https://pharmaphorum.com/sales-marketing/are-dual-arvs-the-new-frontier-in-a-maturing-hiv-market/
Strategic planning in increasingly complex and uncertain markets, the David Cassidy dilemmaThis article is the first in a series of three from Osprey Health Consulting that address the contemporary Share XStrategic planning in increasingly complex and uncertain markets, the David Cassidy dilemmahttps://pharmaphorum.com/views-analysis-sales-marketing/strategic-planning-increasingly-complex-uncertain-markets/
The future biosimilar landscape: the pharmaphorum podcastFor episode 3 of the pharmaphorum podcast Dominic Tyer went to the UK headquarters of Sandoz to meet Share XThe future biosimilar landscape: the pharmaphorum podcasthttps://pharmaphorum.com/sales-marketing/the-future-biosimilar-landscape/
